Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.

被引：0
|
作者：
Kumar, S [1 ]
Lacy, M [1 ]
Inwards, D [1 ]
Litzow, M [1 ]
Tefferi, A [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
804
引用
收藏
页码：192A / 192A
页数：1
相关论文
共 50 条
  • [31] Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation
    D K L Cheuk
    P Wang
    T L Lee
    A K S Chiang
    S Y Ha
    Y L Lau
    G C F Chan
    Bone Marrow Transplantation, 2007, 40 : 935 - 944
  • [32] High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation
    Skeens, Micah A.
    McArthur, Jennifer
    Cheifetz, Ira M.
    Duncan, Christine
    Randolph, Adrienne G.
    Stanek, Joseph
    Lehman, Leslie
    Bajwa, Rajinder
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1823 - 1828
  • [33] Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation
    Cheuk, D. K. L.
    Wang, P.
    Lee, T. L.
    Chiang, A. K. S.
    Ha, S. Y.
    Lau, Y. L.
    Chan, G. C. F.
    BONE MARROW TRANSPLANTATION, 2007, 40 (10) : 935 - 944
  • [34] A Murine Model of Hepatic Veno-occlusive Disease Induced by Allogeneic Hematopoietic Stem Cell Transplantation
    Lingyu Zeng
    Licai An
    Ting Fang
    Bin Pan
    Haiying Sun
    Chong Chen
    Jiang Cao
    Zhenyu Li
    Kailin Xu
    Cell Biochemistry and Biophysics, 2013, 67 : 939 - 948
  • [35] A Murine Model of Hepatic Veno-occlusive Disease Induced by Allogeneic Hematopoietic Stem Cell Transplantation
    Zeng, Lingyu
    An, Licai
    Fang, Ting
    Pan, Bin
    Sun, Haiying
    Chen, Chong
    Cao, Jiang
    Li, Zhenyu
    Xu, Kailin
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2013, 67 (03) : 939 - 948
  • [36] A randomized trial of heparin plus ursodiol versus heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park, SH
    Lee, MH
    Lee, H
    Kim, HS
    Kim, SW
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, CH
    Park, K
    BLOOD, 2001, 98 (11) : 854A - 854A
  • [37] Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg®) with or without hematopoietic stem cell transplantation.
    Erba, HP
    Stadtmauer, EA
    Larson, RA
    Sievers, EL
    Esrey, EH
    Lowenberg, B
    Sherman, ML
    Herbertson, RK
    Appelbaum, FR
    BLOOD, 2003, 102 (11) : 871A - 871A
  • [38] Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
    Lewis, Clinton
    Kim, Haesook T.
    Cutler, Corey S.
    Koreth, John
    Nikiforow, Sarah
    Gooptu, Mahasweta
    Romee, Rizwan
    Glotzbecker, Brett
    Nageshwar, Prashant
    Alyea, Edwin P., III
    Antin, Joseph H.
    Richardson, Paul
    Soiffer, Robert J.
    Ho, Vincent T.
    BLOOD, 2018, 132
  • [39] Efficacy of Low Dose Defibrotide Prevention of Hepatic Veno-Occlusive Disease after Autologous Hematopoietic Stem Cell Transplantation
    Roh, Y. Y.
    Hahn, S. M.
    Choi, Y. H.
    Hong, J. P.
    Lyu, C. J.
    Han, J. W.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S510 - S510
  • [40] Defibrotide for the prevention and treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation; A single center experience
    Antmen, B.
    Sasmaz, I.
    Karagun, B.
    Serbest, M.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S215 - S216
12345